




Nadolol

Revised: October 31, 2018.

CASRN: 42200-33-9



Drug Levels and Effects

Summary of Use during Lactation

Because of its relatively extensive excretion into breastmilk and its renal excretion, other beta-adrenergic blocking drugs are preferred to nadolol, especially while nursing a newborn or preterm infant.

Drug Levels

The excretion of beta-adrenergic blocking drugs into breastmilk is largely determined by their protein binding. Those with low binding are more extensively excreted into breastmilk.[1] Accumulation of the drugs in the infant is related to the fraction excreted in urine. With 25% protein binding, 70% renal excretion and long half-life, nadolol presents a high risk for accumulation in infants, especially neonates. It is estimated that a fully breastfed infant would receive about 5.1% of the maternal weight-adjusted dosage of nadolol.[2]

Maternal Levels. One mother received nadolol 20 mg daily during gestation for hypertension, with the last dose taken 20 hours before delivery. A single sample of breastmilk obtained 38 hours postpartum (58 hours after the last dose) was 146 mcg/L.[3]

After oral doses of 80 mg daily in 12 women, peak nadolol levels occurred in milk at an average of 6 hours after the dose, compared to peak serum levels at 2.7 hours. Serum and milk half-lives were both about 22 hours. Steady-state milk levels occurred after 3 days of therapy; peak milk levels averaged 443 mcg/L and the mean milk levels averaged 357 mcg/L. None of the infants were breastfed.[4][5]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information on nadolol was not found as of the revision date. A study of mothers taking beta-blockers during nursing found a numerically, but not statistically significant increased number of adverse reactions in those taking any beta-blocker. Although the ages of infants were matched to control infants, the ages of the affected infants were not stated. None of the mothers were taking nadolol.[6]

Effects on Lactation and Breastmilk

Relevant published information on the effects of beta-blockade or nadolol during normal lactation was not found as of the revision date. A study in 6 patients with hyperprolactinemia and galactorrhea found no changes in serum prolactin levels following beta-adrenergic blockade with propranolol.[7]

Alternate Drugs to Consider

Propranolol, Labetalol, Metoprolol

References

1. Riant P, Urien S, Albengres E et al. High plasma protein binding as a parameter in the selection of betablockers for lactating women. *Biochem Pharmacol.* 1986;35:4579-81. PubMed PMID: 2878668.
2. Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk. Clinical pharmacokinetic considerations. *Clin Pharmacokinet.* 1988;14:217-40. PubMed PMID: 3292101.
3. Fox RE, Marx C, Stark AR. Neonatal effects of maternal nadolol therapy. *Am J Obstet Gynecol.* 1985;152:1045-6. PubMed PMID: 4025452.
4. Devlin RG, Fleiss PM. Nadolol excretion in human milk. *Clin Pharmacol Ther.* 1981;29:240. Abstract. DOI: [10.1038/clpt.1981.37](https://doi.org/10.1038/clpt.1981.37).
5. Devlin RG, Duchin KL, Fleiss PM. Nadolol in human serum and breast milk. *Br J Clin Pharmacol.* 1981;12:393-6. PubMed PMID: 6117304.
6. Ho TK, Moretti ME, Schaeffer JK et al. Maternal beta-blocker usage and breast feeding in the neonate. *Pediatr Res.* 1999;45:67A. Abstract 385.
7. Board JA, Fierro RJ, Wasserman AJ et al. Effects of alpha- and beta-adrenergic blocking agents on serum prolactin levels in women with hyperprolactinemia and galactorrhea. *Am J Obstet Gynecol.* 1977;127:285-7. PubMed PMID: 556882.

Substance Identification

Substance Name

Nadolol

CAS Registry Number

42200-33-9

Drug Class

Breast Feeding

Lactation

Antihypertensive Agents

Adrenergic Beta-Antagonists

Antiarrhythmics